These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 8314011)

  • 21. [Rapid-acting insulin analogues].
    Matsuda A; Kuzuya T
    Nihon Rinsho; 1999 Mar; 57(3):709-18. PubMed ID: 10199158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Basal activity profiles of NPH and [Nepsilon-palmitoyl Lys (B29)] human insulins in subjects with IDDM.
    Radziuk J; Pye S; Bradley B; Braaten J; Vignati L; Roach P; Bowsher R; DiMarchi R; Chance R
    Diabetologia; 1998 Jan; 41(1):116-20. PubMed ID: 9498640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures.
    Roach P; Woodworth JR
    Clin Pharmacokinet; 2002; 41(13):1043-57. PubMed ID: 12403642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absorption kinetics and action profiles of subcutaneously administered insulin analogues (AspB9GluB27, AspB10, AspB28) in healthy subjects.
    Kang S; Brange J; Burch A; Vølund A; Owens DR
    Diabetes Care; 1991 Nov; 14(11):1057-65. PubMed ID: 1797487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Spanish experience with insulin lispro].
    Reviriego Fernández J
    An Med Interna; 1998 Jul; 15(7):384-90. PubMed ID: 9710993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
    Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles.
    Mudaliar S; Mohideen P; Deutsch R; Ciaraldi TP; Armstrong D; Kim B; Sha X; Henry RR
    Diabetes Care; 2002 Sep; 25(9):1597-602. PubMed ID: 12196433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin lispro: its role in the treatment of diabetes mellitus.
    Campbell RK; Campbell LK; White JR
    Ann Pharmacother; 1996 Nov; 30(11):1263-71. PubMed ID: 8913409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus.
    Wilde MI; McTavish D
    Drugs; 1997 Oct; 54(4):597-614. PubMed ID: 9339963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma insulin and C-peptide after subcutaneous and intravenous administration of human insulin (recombinant DNA) and purified porcine insulin in healthy men.
    Pickup JC; Bilous RW; Viberti GC; Keen H; Jarrett RJ; Glynne A; Cauldwell J; Root M; Rubenstein AH
    Diabetes Care; 1982; 5 Suppl 2():29-34. PubMed ID: 6765536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Insulin Lispro (Lys B28, Pro B29) treatment in adolescents and young people with type 1 diabetes].
    Tuset Castellano MJ; Martínez Badás I; Alonso Blanco M; Barrio Castellanos R
    An Esp Pediatr; 2000 Apr; 52(4):334-8. PubMed ID: 11003924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Action profile of the rapid acting insulin analogue: human insulin B28Asp.
    Heinemann L; Heise T; Jorgensen LN; Starke AA
    Diabet Med; 1993 Jul; 10(6):535-9. PubMed ID: 8365089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.
    Pettis RJ; Ginsberg B; Hirsch L; Sutter D; Keith S; McVey E; Harvey NG; Hompesch M; Nosek L; Kapitza C; Heinemann L
    Diabetes Technol Ther; 2011 Apr; 13(4):435-42. PubMed ID: 21355718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin pharmacokinetics following continuous infusion and bolus injection of regular porcine and human insulin in healthy man.
    Waldhäusl WK; Bratusch-Marrain PR; Vierhapper H; Nowotny P
    Metabolism; 1983 May; 32(5):478-86. PubMed ID: 6341763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients.
    Bruttomesso D; Pianta A; Mari A; Valerio A; Marescotti MC; Avogaro A; Tiengo A; Del Prato S
    Diabetes; 1999 Jan; 48(1):99-105. PubMed ID: 9892228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.
    von Mach MA; Brinkmann C; Hansen T; Weilemann LS; Beyer J
    Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):416-9. PubMed ID: 12518253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of physicochemical variables of regular insulin formulations on their absorption from the subcutaneous tissue.
    Polaschegg E
    Diabetes Res Clin Pract; 1998 Apr; 40(1):39-44. PubMed ID: 9699089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamics of insulin Lispro in 2 patients with type II diabetes mellitus.
    Jehle PM; Fussgänger RD; Seibold A; Lüttke B; Böhm BO
    Int J Clin Pharmacol Ther; 1996 Nov; 34(11):498-503. PubMed ID: 8937933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.